

Amendments to the Claims

This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims

28. (previously presented) A method for inducing cytotoxicity in a cell comprising: administering to the cell a cytotoxic dose of a cathepsin inhibitor, wherein the cathepsin inhibitor is CATI-1 (Z-Phe-Gly-NHO-Bz; where Z is benzyloxycarbonyl, -NHO- is hydroxylamine linkage, and Bz is benzoyl).
29. (previously presented) The method of claim 28, wherein the cell is a cancer cell.
30. (previously presented) The method of claim 29, wherein the cancer is a solid tumor.
31. (previously presented) The method of claim 29, wherein the cancer is prostate cancer.
32. (previously presented) The method of claim 29, wherein the cancer is breast cancer.
33. (previously presented) The method of claim 29, wherein the cancer is a brain tumor.
34. (previously presented) The method of claim 29, wherein the cancer is leukemia.
35. (previously presented) The method of claim 28, wherein cytotoxicity results from apoptosis.

36. (previously presented) The method of claim 35, wherein the cathepsin inhibitor is administered by expressing a heterologous nucleic acid sequence encoding CATI-1 (Z-Phe-Gly-NHO-Bz; where Z is benzyloxycarbonyl, -NHO- is hydroxylamine linkage, and Bz is benzoyl) in the cell; wherein the cell has enhanced cathepsin activity as compared to control host cells.

37. (previously presented) A method for inhibiting inflammatory disease states in a subject comprising administering to the subject a cathepsin inhibitor.

38. (previously presented) The method of claim 37, wherein the cathepsin inhibitor is CATI-1 (Z-Phe-Gly-NHO-Bz; where Z is benzyloxycarbonyl, -NHO- is hydroxylamine linkage, and Bz is benzoyl).

39. (previously presented) The method of claim 37, wherein the inflammatory disease is rheumatoid arthritis.

40. (previously presented) The method of claim 37, wherein the inflammatory disease is osteoarthritis.